A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy.

Trial Profile

A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Tecemotide (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 23 Nov 2014 Planned End Date changed from 1 Jun 2022 to 1 Mar 2015 as reported by ClinicalTrials.gov
    • 12 Sep 2014 Status changed from recruiting to discontinued, as reported in a Merck KGaA media release.
    • 22 Aug 2013 Planned end date changed from 1 Oct 2018 to 1 Jun 2022 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top